Related Experiment Videos
[Indications for labile blood products]
1michel.jeanne@efs.sante.fr
La Revue Du Praticien
|August 16, 2001
Summary
Blood transfusion therapy provides essential blood products like red cells and plasma. Careful use and leukoreduction minimize risks, ensuring product availability and patient safety.
Area of Science:
- Hematology
- Transfusion Medicine
Context:
- Blood transfusion therapy aims to supply specific labile blood products.
- Available products include red blood cell concentrates, platelet concentrates, and fresh frozen plasma.
- Product selection and adaptation are based on biological parameters.
Purpose:
- To optimize the use of blood products, considering their rarity and cost.
- To inform clinicians about appropriate blood product indications, preventing misuse.
- To continuously assess the benefit-risk ratio of transfusions.
Summary:
- Blood products carry risks such as immunologic reactions and transfusion-transmitted diseases.
- Systematic leukoreduction of cellular blood products since 1998 has reduced these risks.
- Plasma leukoreduction and limiting transfusion numbers are considered for prion transmission risk.
Impact:
- Ensures better tolerance and reduced adverse effects through leukoreduction.
- Promotes rational prescribing to maintain blood product availability for all patients.
- Addresses emerging concerns like prion transmission in transfusion medicine.